A new genetic study is helping explain why some people feel amazing on GLP‑1 medications and others feel like they’re about to hurl. Plot twist: your genetics may have a lot to do with the reason some people feel sick or don’t lose weight while taking weight loss medications like Ozempic, Wegovy, and Mounjaro. Your response to these meds is not a personal failure. It is biology. And a lot of that biology is written in your genes.

Plot twist: your genetics may have a lot to do with the reason some people feel sick or don’t lose weight while taking weight loss medications like Ozempic, Wegovy, and Mounjaro.

GLP‑1 medications like semaglutide and tirzepatide work by increasing satiety, slowing digestion, and improving blood sugar control. Those effects can lead to weight loss for many people, but weight change is only one outcome. The real story is how these drugs shift appetite signals, cravings, and metabolic regulation.

Disclosure: This blog post contains affiliate links. By clicking the affiliate links in this post, you not only get to find great products at no extra cost but also support my blog, as I may receive a small commission on purchases made through these links.

Genetics and Why People Respond Differently

The study, published in Nature, looked at more than 27,000 people using GLP‑1 medications. Two genes stood out.

GLP1R. A specific variant made the GLP‑1 receptor more responsive. People with this variant tended to feel stronger satiety effects and often saw more weight change. They also had a higher chance of nausea.
GIPR. This one mattered mostly for tirzepatide users. A certain variant increased the risk of vomiting and reduced the usual protective effect against nausea.

This is the beginning of precision metabolic care. Not weight‑centric care. Not shame‑based care. Actual personalized treatment based on how your body works.

Here’s a Curveball: Differences Across Populations

The study also found that average responses varied across ancestry groups. People with European ancestry showed the largest weight changes. People with African ancestry showed the smallest. But there’s some nuance to be found here; this does not mean the medications are less effective for certain groups. It means the measurements we use are shaped by history, genetics, environment, and the biases baked into clinical research.

This is where Sabrina Strings’ work in Fearing the Black Body: The Racial Origins of Fatphobia can offer some context. Strings shows that our modern definitions of “obesity” were built on Eurocentric data and colonial beauty standards. Thinness was elevated as a racial ideal during the 18th and 19th centuries, while Black and Indigenous bodies were pathologized. So, when a study reports differences in “weight‑loss response,” we have to remember that the categories themselves were created through a racialized lens, not neutral science.

In fact, a better way to look at weight gain is through the lens of “symptom” rather than “cause,” according to the Cleveland Clinic. Not only is it scientifically more correct, but it also offers the opportunity for self-compassion, a must for anyone living in a bigger body.

Side Effects and Predictive Patterns

Most people in the study had little or no nausea. A smaller group had moderate or severe symptoms. Genetic variants helped explain some of that. When researchers combined genetic data with clinical factors, they could partially predict who might feel more satiety, who might see bigger improvements in blood sugar, and who might be more prone to side effects.

Reframing What Success Looks Like

The median participant saw about an 11 to 12 percent reduction in body weight. Some saw more. Some saw none. But the more important point is that GLP‑1 medications consistently improved appetite regulation and metabolic markers. Those are the things that actually drive long‑term health.

Weight loss can be part of the story, but it is not the whole story. And it should never be the moral center of the story. Strings’ work reminds us that weight‑centric narratives have been used to uphold racial hierarchies, not health.

What To Do About It

Everyone’s reason for choosing a GLP-1 medication is unique to them; depending on their motivation for using one, some will choose to stay on their medication, while others may stop. For some, a holistic approach might make more sense: exercise regularly, follow a diet high in fiber and protein and low in sugar, and supplement with berberine, which works somewhat similarly to drugs like Metformin.

Where This Is Going

The study’s authors note that genetic variation plays a real role in how people respond. This opens the door to more personalized, humane, and non‑stigmatizing metabolic care. Instead of treating weight as the only metric that matters, a proper care model should focus on satiety, energy, blood sugar stability, and overall well‑being. Those outcomes matter at every size.

Feeling Sick or Not Losing Weight On GLP-1? Your Genes Might Be the Reason.

Genetics and Why People Respond Differently

Here’s a Curveball: Differences Across Populations

Reframing What Success Looks Like

What To Do About It

Where This Is Going

Related Blog Posts

Join our email list! You won’t be sorry.